Home » Synta Announces First Patient Treated in the Galaxy Trial a Phase IIb/III Trial for Ganetespib in Advanced 2nd-line Non-small Cell Lung Cancer
Synta Announces First Patient Treated in the Galaxy Trial a Phase IIb/III Trial for Ganetespib in Advanced 2nd-line Non-small Cell Lung Cancer
Synta Pharmaceuticals announced that the first patient has been treated in a Phase IIb/III clinical trial of ganetespib in combination with docetaxel in non-small cell lung cancer.
MarketWatch
MarketWatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May